|
||||||
|
 | |
| |
| Differntial gene expression between RNA A-to-I edited tumor samples versus normal samples |
| |
| |
| The effects of the RNA editing to the stability of the RNA structures |
| |
| |
| |
| |
|
Editing gene: FOS (CAeditome ID:2353) |
Gene summary for FOS |
 Gene summary |
| Gene information | Gene symbol | FOS | Gene ID | 2353 |
| Gene name | Fos proto-oncogene, AP-1 transcription factor subunit | |
| Synonyms | AP-1|C-FOS|p55 | |
| Cytomap | 14q24.3 | |
| Type of gene | protein-coding | |
| Description | proto-oncogene c-FosFBJ murine osteosarcoma viral (v-fos) oncogene homolog (oncogene FOS)FBJ murine osteosarcoma viral oncogene homologFos proto-oncogene, AP-1 trancription factor subunitG0/G1 switch regulatory protein 7activator protein 1cellular o | |
| Modification date | 20210531 | |
| UniProtAcc | P01100 | |
| Context |
| Gene ontology of each this gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Gene | GO ID | GO term | PubMed ID |
| FOS | GO:0000976 | Proto-oncogene c-Fos | 9732876 |
| FOS | GO:0003700 | Proto-oncogene c-Fos | 9732876 |
| FOS | GO:1990837 | Proto-oncogene c-Fos | 28473536 |
| FOS | GO:0007179 | Proto-oncogene c-Fos | 9732876 |
| FOS | GO:0034614 | Proto-oncogene c-Fos | 17217916 |
| FOS | GO:0045893 | Proto-oncogene c-Fos | 9732876 |
| FOS | GO:0045944 | Proto-oncogene c-Fos | 10508860 |
| FOS | GO:0060395 | Proto-oncogene c-Fos | 9732876 |
| FOS | GO:0005634 | Proto-oncogene c-Fos | 22387553 |
| FOS | GO:0005634 | Proto-oncogene c-Fos | 24184327 |
| FOS | GO:0005654 | Proto-oncogene c-Fos | 0000052 |
| FOS | GO:0035976 | Proto-oncogene c-Fos | 10508860 |
Top |
RNA A-to-I events for FOS |
| RNA A-to-I editing events across TCGA 33 cancers data sets based on Ensembl gene isoform structure. |
 |
| RNA editing frequencies across 33 cancers of gene: ENSG00000170345.8 |
| RNA A-to-I editing events in Cancer. |
| CAediting_1006725(75279458, +), CAediting_1006726(75280392, +), CAediting_1006727(75280904, +), |
Top |
RNA editing positional annotations for FOS using Annovar |
| Protein coding RNA editing(s). |
| CAeditome ID | Position | Variant type | ENST | NTchange | AAchange | SIFT_score | Polyphen2_HVAR_score | PROVEAN_pred |
| CAediting_1006727 | chr14_75280904_+ | nonsynonymous SNV | ENST00000303562.7 | c.A623G | p.D208G | D | B | D |
| CAediting_1006727 | chr14_75280904_+ | nonsynonymous SNV | ENST00000535987.4 | c.A515G | p.D172G | D | B | D |
| CAediting_1006727 | chr14_75280904_+ | nonsynonymous SNV | ENST00000555347.1 | c.A179G | p.D60G | D | B | D |
| CAediting_1006727 | chr14_75280904_+ | nonsynonymous SNV | ENST00000555672.1 | c.A173G | p.D58G | D | B | D |
| CAediting_1006727 | chr14_75280904_+ | nonsynonymous SNV | ENST00000555686.1 | c.A281G | p.D94G | D | B | D |
| Gene structure information of RNA editing(s). |
| CAeditome ID | Position | Variant type |
| CAediting_1006725 | chr14_75279458_+ | ncRNA_exonic |
| CAediting_1006726 | chr14_75280392_+ | UTR5 |
| CAediting_1006727 | chr14_75280904_+ | exonic |
| Repat-regional RNA editing(s). |
| CAeditome ID | Position | Repeat family | Repeat sub family | Repeat name |
Top |
RNA A-to-I editing events in the alternative splicing sites for FOS |
| RNA A-to-I editing(s) in the alternative splicing sites. |
| AStype | CAeditomID | Editing position | AS position | AS direction | Exonic location | Wildtype sequence | Wildtype splicing strength | RNA edited sequence | RNA edited splicing strength |
| Differential percent of spliced in (PSI) between RNA A-to-I edited and non-edited samples for ENSG00000170345.8.FOS. |
| Correlation between RNA A-to-I editing and PSI for ENSG00000170345.8.FOS. |
Top |
Differntial gene expression between RNA A-to-I edited versus non-edited samples for FOS |
| Differential gene expressions between RNA A-to-I edited and non-edited tumor samples. * The grey color means N/A. |
| Correlation between RNA A-to-I editing and gene expression. |
| - Differentially expressed gene between RNA A-to-I edited samples versus non-edited samples. * Click on the image to enlarge it in a new window. |
Top |
Protein coding region RNA A-to-I editings for FOS |
| - Lollipop plot for RNA A-to-I editings across protein structure. * Click on the image to enlarge it in a new window. |
 |
Top |
The effects of the RNA editing to the miRNA binding sites for FOS |
| **If you are searching a miRNA gene with RNA editing events in its seed regions, please see the search pages of miRNA targets to discover the effects of this RNA editing event to miRNA regulations. For more information, please check the files in the Download page. |
| RNA A-to-I editing in the 3'-UTR regions of mRNA gained miRNA binding sites. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| RNA A-to-I editing in the 3'-UTR regions of mRNA lost miRNA binding sites. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| RNA A-to-I editing in lncRNA gained miRNA binding sites. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| RNA A-to-I editing in lncRNA lost miRNA binding sites. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| RNA A-to-I editing in miRNAs gained binding to lncRNA. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| RNA A-to-I editing in miRNAs lost binding to lncRNA. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| RNA A-to-I editing in miRNAs gained binding to the 3'-UTR region of mRNA. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| CAediting_688081 | chr9_63819627_+ | ENSG00000170345.8 | ENST00000554617 | hsa-miR-4477b | 75280327 | 75280333 | 7mer-m8 | 75280311 | 75280334 | 148 | -15.41 |
| CAediting_396018 | chr5_1062918_- | ENSG00000170345.8 | ENST00000535987 | hsa-miR-4635 | 75281571 | 75281577 | 7mer-m8 | 75281558 | 75281578 | 153 | -20.74 |
| CAediting_117844 | chr1_162342605_+ | ENSG00000170345.8 | ENST00000303562 | hsa-miR-556-3p | 75281852 | 75281858 | 7mer-m8 | 75281838 | 75281859 | 157 | -12.61 |
| CAediting_396018 | chr5_1062918_- | ENSG00000170345.8 | ENST00000303562 | hsa-miR-4635 | 75281571 | 75281577 | 7mer-m8 | 75281558 | 75281578 | 153 | -20.74 |
| CAediting_396018 | chr5_1062918_- | ENSG00000170345.8 | ENST00000555686 | hsa-miR-4635 | 75281571 | 75281577 | 7mer-m8 | 75281558 | 75281578 | 153 | -20.74 |
| CAediting_396018 | chr5_1062918_- | ENSG00000170345.8 | ENST00000555347 | hsa-miR-4635 | 75281571 | 75281577 | 7mer-m8 | 75281558 | 75281578 | 153 | -20.74 |
| RNA A-to-I editing in miRNAs lost binding to the 3'-UTR mRNA. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| Differentially expressed gene-miRNA network |
Top |
The effects of the RNA editing to the stability of the RNA structures for FOS |
| - RNA A-to-I editing in mRNA. * Click on the image to enlarge it in a new window. |
| ENST | ENST type | RNA structure without RNA A-to-I editing. | RNA structure with RNA A-to-I editing. |
| RNA A-to-I editing in RNA structures for Minimum free energy (MFE). |
| CAeditom_ID | ENST | Editing_Position | MFE_withoneAI | MFE_withoutAI | MFE_withmultipleAI |
Top |
Relation with ADAR for FOS |
| Correlation between ADAR gene expression and RNA editing frequency |
| Cancer | CAeditomID | position | ADAR1 (p-val) | ADAR1 (coeff.) | ADAR2 (p-val) | ADAR2 (coeff.) | ADAR3 (p-val) | ADAR3 (coeff.) |
Top |
Relation with cancer stages for FOS |
| Correlation between Cancer stages and RNA editing frequency |
| Cancer | Stage_type | CAeditomID | position | P-val | Coeff. |
Top |
Relation with survival for FOS |
| Correlation between RNA editing and survival |
| Cancer | CAeditomID | position | KMpvalue | Coxpvalue | CoxHR |
Top |
RelatedDrugs for FOS |
| Approved drugs targeting this gene. (DrugBank Version 5.1.8 2021-01-03) |
| Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| FOS | P01100 | DB00852 | Pseudoephedrine | Proto-oncogene c-Fos | SmallMoleculeDrug | approved |
| FOS | P01100 | DB08813 | Nadroparin | Proto-oncogene c-Fos | SmallMoleculeDrug | approved|investigational |
Top |
RelatedDiseases for FOS |
| Diseases associated with this gene. (DisGeNet 7.0) |
| Gene | Disease ID | Disease name | # pubmeds | Source |
| FOS | C0022333 | Jacksonian Seizure | 4 | CTD_human |
| FOS | C0036572 | Seizures | 4 | CTD_human |
| FOS | C0038220 | Status Epilepticus | 4 | CTD_human |
| FOS | C0149958 | Complex partial seizures | 4 | CTD_human |
| FOS | C0234533 | Generalized seizures | 4 | CTD_human |
| FOS | C0234535 | Clonic Seizures | 4 | CTD_human |
| FOS | C0270823 | Petit mal status | 4 | CTD_human |
| FOS | C0270824 | Visual seizure | 4 | CTD_human |
| FOS | C0270844 | Tonic Seizures | 4 | CTD_human |
| FOS | C0270846 | Epileptic drop attack | 4 | CTD_human |
| FOS | C0311335 | Grand Mal Status Epilepticus | 4 | CTD_human |
| FOS | C0393734 | Complex Partial Status Epilepticus | 4 | CTD_human |
| FOS | C0422850 | Seizures, Somatosensory | 4 | CTD_human |
| FOS | C0422852 | Seizures, Auditory | 4 | CTD_human |
| FOS | C0422853 | Olfactory seizure | 4 | CTD_human |
| FOS | C0422854 | Gustatory seizure | 4 | CTD_human |
| FOS | C0422855 | Vertiginous seizure | 4 | CTD_human |
| FOS | C0494475 | Tonic - clonic seizures | 4 | CTD_human |
| FOS | C0751056 | Non-epileptic convulsion | 4 | CTD_human |
| FOS | C0751110 | Single Seizure | 4 | CTD_human |
| FOS | C0751123 | Atonic Absence Seizures | 4 | CTD_human |
| FOS | C0751494 | Convulsive Seizures | 4 | CTD_human |
| FOS | C0751495 | Seizures, Focal | 4 | CTD_human |
| FOS | C0751496 | Seizures, Sensory | 4 | CTD_human |
| FOS | C0751522 | Status Epilepticus, Subclinical | 4 | CTD_human |
| FOS | C0751523 | Non-Convulsive Status Epilepticus | 4 | CTD_human |
| FOS | C0751524 | Simple Partial Status Epilepticus | 4 | CTD_human |
| FOS | C3495874 | Nonepileptic Seizures | 4 | CTD_human |
| FOS | C4048158 | Convulsions | 4 | CTD_human |
| FOS | C4316903 | Absence Seizures | 4 | CTD_human |
| FOS | C4317109 | Epileptic Seizures | 4 | CTD_human |
| FOS | C4317123 | Myoclonic Seizures | 4 | CTD_human |
| FOS | C4505436 | Generalized Absence Seizures | 4 | CTD_human |
| FOS | C0009171 | Cocaine Abuse | 3 | CTD_human |
| FOS | C0038587 | Substance Withdrawal Syndrome | 3 | CTD_human |
| FOS | C0086189 | Drug Withdrawal Symptoms | 3 | CTD_human |
| FOS | C0087169 | Withdrawal Symptoms | 3 | CTD_human |
| FOS | C0236736 | Cocaine-Related Disorders | 3 | CTD_human |
| FOS | C0600427 | Cocaine Dependence | 3 | CTD_human |
| FOS | C0020538 | Hypertensive disease | 2 | CTD_human |
| FOS | C2239176 | Liver carcinoma | 2 | CTD_human |
| FOS | C0003469 | Anxiety Disorders | 1 | CTD_human |
| FOS | C0005398 | Cholestasis, Extrahepatic | 1 | CTD_human |
| FOS | C0006142 | Malignant neoplasm of breast | 1 | CTD_human |
| FOS | C0007621 | Neoplastic Cell Transformation | 1 | CTD_human |
| FOS | C0011859 | Lipoatrophic Diabetes Mellitus | 1 | ORPHANET |
| FOS | C0014175 | Endometriosis | 1 | CTD_human |
| FOS | C0014544 | Epilepsy | 1 | CTD_human |
| FOS | C0016063 | Osteitis Fibrosa Disseminata | 1 | CTD_human |
| FOS | C0019080 | Hemorrhage | 1 | CTD_human |
| FOS | C0020429 | Hyperalgesia | 1 | CTD_human |
| FOS | C0023893 | Liver Cirrhosis, Experimental | 1 | CTD_human |
| FOS | C0024121 | Lung Neoplasms | 1 | CTD_human |
| FOS | C0027765 | nervous system disorder | 1 | CTD_human |
| FOS | C0035126 | Reperfusion Injury | 1 | CTD_human |
| FOS | C0040997 | Trigeminal Neuralgia | 1 | CTD_human |
| FOS | C0086237 | Epilepsy, Cryptogenic | 1 | CTD_human |
| FOS | C0087031 | Juvenile-Onset Still Disease | 1 | CTD_human |
| FOS | C0149504 | Encephalopathy, Toxic | 1 | CTD_human |
| FOS | C0154659 | Toxic Encephalitis | 1 | CTD_human |
| FOS | C0221032 | Familial generalized lipodystrophy | 1 | ORPHANET |
| FOS | C0235032 | Neurotoxicity Syndromes | 1 | CTD_human |
| FOS | C0236018 | Aura | 1 | CTD_human |
| FOS | C0236733 | Amphetamine-Related Disorders | 1 | CTD_human |
| FOS | C0236804 | Amphetamine Addiction | 1 | CTD_human |
| FOS | C0236807 | Amphetamine Abuse | 1 | CTD_human |
| FOS | C0238281 | Middle Cerebral Artery Syndrome | 1 | CTD_human |
| FOS | C0242379 | Malignant neoplasm of lung | 1 | CTD_human |
| FOS | C0269102 | Endometrioma | 1 | CTD_human |
| FOS | C0376280 | Anxiety States, Neurotic | 1 | CTD_human |
| FOS | C0393786 | Trigeminal Neuralgia, Idiopathic | 1 | CTD_human |
| FOS | C0393787 | Secondary Trigeminal Neuralgia | 1 | CTD_human |
| FOS | C0458247 | Allodynia | 1 | CTD_human |
| FOS | C0678222 | Breast Carcinoma | 1 | CTD_human |
| FOS | C0740376 | Middle Cerebral Artery Thrombosis | 1 | CTD_human |
| FOS | C0740391 | Middle Cerebral Artery Occlusion | 1 | CTD_human |
| FOS | C0740392 | Infarction, Middle Cerebral Artery | 1 | CTD_human |
| FOS | C0751111 | Awakening Epilepsy | 1 | CTD_human |
| FOS | C0751211 | Hyperalgesia, Primary | 1 | CTD_human |
| FOS | C0751212 | Hyperalgesia, Secondary | 1 | CTD_human |
| FOS | C0751213 | Tactile Allodynia | 1 | CTD_human |
| FOS | C0751214 | Hyperalgesia, Thermal | 1 | CTD_human |
| FOS | C0751217 | Hyperkinesia, Generalized | 1 | CTD_human |
| FOS | C0751845 | Middle Cerebral Artery Embolus | 1 | CTD_human |
| FOS | C0751846 | Left Middle Cerebral Artery Infarction | 1 | CTD_human |
| FOS | C0751847 | Embolic Infarction, Middle Cerebral Artery | 1 | CTD_human |
| FOS | C0751848 | Thrombotic Infarction, Middle Cerebral Artery | 1 | CTD_human |
| FOS | C0751849 | Right Middle Cerebral Artery Infarction | 1 | CTD_human |
| FOS | C1257931 | Mammary Neoplasms, Human | 1 | CTD_human |
| FOS | C1279420 | Anxiety neurosis (finding) | 1 | CTD_human |
| FOS | C1458155 | Mammary Neoplasms | 1 | CTD_human |
| FOS | C1862939 | AMYOTROPHIC LATERAL SCLEROSIS 1 | 1 | CTD_human |
| FOS | C1862941 | Amyotrophic Lateral Sclerosis, Sporadic | 1 | CTD_human |
| FOS | C2936719 | Mechanical Allodynia | 1 | CTD_human |
| FOS | C3495559 | Juvenile arthritis | 1 | CTD_human |
| FOS | C3714758 | Juvenile psoriatic arthritis | 1 | CTD_human |
| FOS | C3887506 | Hyperkinesia | 1 | CTD_human |
| FOS | C4551993 | Amyotrophic Lateral Sclerosis, Familial | 1 | CTD_human |
| FOS | C4552091 | Polyarthritis, Juvenile, Rheumatoid Factor Negative | 1 | CTD_human |
| FOS | C4704862 | Polyarthritis, Juvenile, Rheumatoid Factor Positive | 1 | CTD_human |
| FOS | C4704874 | Mammary Carcinoma, Human | 1 | CTD_human |
| FOS | C4704884 | Fibrocystic Dysplasia of Bone | 1 | CTD_human |
| FOS | C4704885 | Fibrocartilaginous Dysplasia of Bone | 1 | CTD_human |
| FOS | C4721610 | Carcinoma, Ovarian Epithelial | 1 | CTD_human |
